DK0831769T3 - Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser - Google Patents
Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelserInfo
- Publication number
- DK0831769T3 DK0831769T3 DK96924268T DK96924268T DK0831769T3 DK 0831769 T3 DK0831769 T3 DK 0831769T3 DK 96924268 T DK96924268 T DK 96924268T DK 96924268 T DK96924268 T DK 96924268T DK 0831769 T3 DK0831769 T3 DK 0831769T3
- Authority
- DK
- Denmark
- Prior art keywords
- thyroid hormone
- thyroid
- compound
- concentration
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48169895A | 1995-06-07 | 1995-06-07 | |
PCT/US1996/009975 WO1996040048A2 (en) | 1995-06-07 | 1996-06-07 | Novel uses for thyroid hormones or thyroid hormone-like compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0831769T3 true DK0831769T3 (da) | 2004-02-23 |
Family
ID=23913014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96924268T DK0831769T3 (da) | 1995-06-07 | 1996-06-07 | Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0831769B2 (de) |
JP (1) | JPH11508241A (de) |
AT (1) | ATE251887T1 (de) |
AU (1) | AU6476996A (de) |
CA (1) | CA2223720C (de) |
DE (1) | DE69630380T8 (de) |
DK (1) | DK0831769T3 (de) |
ES (1) | ES2208753T5 (de) |
PT (1) | PT831769E (de) |
WO (1) | WO1996040048A2 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380255B1 (en) * | 1995-06-07 | 2002-04-30 | Karo Bio Ab | Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds |
WO1997036570A1 (de) * | 1996-03-29 | 1997-10-09 | S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner | Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite' |
US6054485A (en) * | 1996-08-20 | 2000-04-25 | Regents Of The University Of California | Eye treatments using synthetic thyroid hormone compositions |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
JP2002542284A (ja) * | 1999-04-26 | 2002-12-10 | ダンフォース,エリオット,ジュニア | テトラックの薬学組成物およびその使用方法 |
US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
EP1253966B1 (de) * | 1999-08-13 | 2011-04-27 | Curadis GmbH | Substanzen und mittel zur positiven beeinflussung von kollagen |
WO2001036351A2 (en) * | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
FI107018B (fi) * | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatologinen käyttö ja valmiste |
AU2002331145B2 (en) * | 2001-08-24 | 2008-07-10 | Karo Bio Ab | Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
EP2335694B1 (de) | 2003-09-15 | 2018-06-13 | NanoPharmaceuticals LLC | Thyroidhormon-analoga und deren verwendung |
US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
US8071134B2 (en) | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
US9220788B2 (en) | 2009-06-17 | 2015-12-29 | Nanopharmaceuticals Llc | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
WO2007035612A2 (en) | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
WO2007059039A1 (en) * | 2005-11-11 | 2007-05-24 | Oregon Health & Science University | Thyroxine derivatives for preconditioning against stroke |
CA2648243C (en) * | 2006-04-11 | 2015-12-22 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
AU2007353426A1 (en) | 2006-12-22 | 2008-11-20 | Albany College Of Pharmacy And Health Sciences | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
WO2010120506A1 (en) | 2009-03-31 | 2010-10-21 | Ordway Research Institute, Inc. | Combination treatment of cancer with cetuximab and tetrac |
US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
WO2015074050A1 (en) | 2013-11-18 | 2015-05-21 | Nanopharmaceuticals Llc | Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof |
MX363010B (es) | 2014-11-25 | 2019-03-04 | Trophea Dev Ab | Tratamiento de la atrofia de piel con una combinacion de acido triyodotiroacetico (triac) y dehidroepiandrosterona (dhea). |
WO2017214299A1 (en) | 2016-06-07 | 2017-12-14 | Nanopharmaceuticals, Llc | NON-CLEAVABLE POLYMER CONJUGATED WITH αvβ3 INTEGRIN THYROID ANTAGONISTS |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
WO2018226604A1 (en) | 2017-06-05 | 2018-12-13 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
EP3768690A4 (de) | 2018-03-22 | 2021-11-24 | Viking Therapeutics, Inc. | Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung |
US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE515812A (de) * | ||||
GB782745A (en) * | 1953-08-13 | 1957-09-11 | Arthur Alfred Hellbaum | Improvements in or relating to pharmaceutical compositions |
GB859546A (en) * | 1956-05-29 | 1961-01-25 | Arthur Alfred Hellbaum | Composition for treatment of the skin |
US3198702A (en) * | 1960-03-17 | 1965-08-03 | Arthur A Hellbaum | Method for treating skin burns |
FR3111M (fr) * | 1963-12-02 | 1965-02-08 | Rech S Pharma Et Scient | Médicament a base de dérivé de cystéine. |
FR6656M (de) * | 1967-02-23 | 1969-01-27 | ||
FR2139748B1 (de) * | 1971-06-03 | 1974-08-30 | Theranol Lab | |
GB1400851A (en) * | 1971-06-23 | 1975-07-16 | Egema Sa | Triidothyroalkyl compounds their method of preparation and therapeutical compositions containing such compounds |
FR2160258A1 (en) * | 1971-11-16 | 1973-06-29 | Egema | Triiodothyroalkanoic acid derivs - for treating lipid overload and celluitis |
FR2142675A1 (en) * | 1971-06-23 | 1973-02-02 | Egema Sa | Triiodothyroalkanoic acid derivs - for treating lipid overload and celluitis |
FR2153202A1 (en) * | 1971-09-24 | 1973-05-04 | Ind Chimique | Triiodothyroacetic acid salts prepn - with metals and organic bases |
FR2197577A1 (en) * | 1972-08-30 | 1974-03-29 | Ind Chimi Ue Sa | Hypocholesterolaemic, antiatheroma agents - 3,5-diiodo-4-(3-iodo-4-alkoxy-carbonyl phenoxy) phenylalkanoic acids, esters and salts |
CH622703A5 (en) * | 1976-06-10 | 1981-04-30 | Berema Sa | Therapeutic compositions for treating deposits of excess fat and infiltrates causing cellulite |
FR2356427A2 (fr) * | 1976-07-02 | 1978-01-27 | Ana Laboratoires | Nouveaux medicaments pour le traitement des surcharges lipidiques et de la cellulite |
FR2357246A1 (fr) * | 1976-07-09 | 1978-02-03 | Martinez Gerard | Nouvelles compositions therapeutiques douees d'activite anti-inflammatoire, antalgique et anti-cellulitique |
GB1587638A (en) * | 1977-06-03 | 1981-04-08 | Berema Sa | Iodophenoxyphenylalkenoic acid derivatives and pharmaceutical preparations containing them |
RO76691A2 (ro) * | 1979-04-02 | 1981-08-30 | Intreprinderea De Produse Cosmetice "Farmec",Ro | Crema nutritiva impotriva ridurilor |
CH642851A5 (en) * | 1980-02-13 | 1984-05-15 | Berema Sa | Medicinal compositions for the treatment of cellulite |
FR2501505A1 (fr) * | 1981-03-11 | 1982-09-17 | Ana Laboratoires | Nouveaux medicaments destines au traitement des hyperlipidemies et hypercholesterolemies a base d'acide 3,5-diiodo-3'-isopropyl-thyroacetique |
FI107018B (fi) * | 2000-04-06 | 2001-05-31 | Ipsat Therapies Oy | Dermatologinen käyttö ja valmiste |
-
1996
- 1996-06-07 EP EP96924268A patent/EP0831769B2/de not_active Expired - Lifetime
- 1996-06-07 AT AT96924268T patent/ATE251887T1/de not_active IP Right Cessation
- 1996-06-07 ES ES96924268T patent/ES2208753T5/es not_active Expired - Lifetime
- 1996-06-07 DE DE69630380T patent/DE69630380T8/de active Active
- 1996-06-07 DK DK96924268T patent/DK0831769T3/da active
- 1996-06-07 JP JP9502122A patent/JPH11508241A/ja active Pending
- 1996-06-07 PT PT96924268T patent/PT831769E/pt unknown
- 1996-06-07 EP EP03022417A patent/EP1398024A3/de not_active Withdrawn
- 1996-06-07 WO PCT/US1996/009975 patent/WO1996040048A2/en active IP Right Grant
- 1996-06-07 AU AU64769/96A patent/AU6476996A/en not_active Abandoned
- 1996-06-07 CA CA002223720A patent/CA2223720C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0831769B1 (de) | 2003-10-15 |
EP1398024A2 (de) | 2004-03-17 |
WO1996040048A2 (en) | 1996-12-19 |
EP0831769B2 (de) | 2008-07-23 |
EP0831769A2 (de) | 1998-04-01 |
DE69630380T2 (de) | 2004-08-12 |
ES2208753T3 (es) | 2004-06-16 |
ATE251887T1 (de) | 2003-11-15 |
CA2223720C (en) | 2008-12-30 |
DE69630380D1 (de) | 2003-11-20 |
PT831769E (pt) | 2004-02-27 |
DE69630380T3 (de) | 2009-04-30 |
DE69630380T8 (de) | 2009-08-06 |
AU6476996A (en) | 1996-12-30 |
ES2208753T5 (es) | 2009-02-01 |
JPH11508241A (ja) | 1999-07-21 |
EP1398024A3 (de) | 2004-12-15 |
CA2223720A1 (en) | 1996-12-19 |
WO1996040048A3 (en) | 1997-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0831769T3 (da) | Hidtil ukendte anvendelser af thyroideahormoner eller thyroideahormon-lignende forbindelser | |
WO1994012880A3 (en) | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression | |
AR062931A2 (es) | Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos | |
DE69829183D1 (de) | Synthese und verwendung von retinoiden mit negativen hormonellen und/oder antagonistischen wirkungen | |
BR9810378A (pt) | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero | |
ATE197763T1 (de) | Zusammensetzungen, welche ein rar alpha spezifischer liganden und mindestens eine fettsäure enthalten | |
UA66750C2 (en) | Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors | |
NO20003552D0 (no) | Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte | |
WO1997009297A3 (en) | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities | |
GEP19991704B (en) | Carbon Derivatives, Method for Its Production, Compositions Based Thereon | |
DE68920128T2 (de) | Sulfonsäure-substituierte aromatische Steroide als 5-Alpha-Reduktase-Inhibitoren. | |
BR0013597A (pt) | Compostos e métodos moduladores de receptor de androgênio | |
NZ331941A (en) | Pentafluorobenzenesulfonamides and analogs and use in regulation of LDL receptor synthesis | |
NL300017I2 (nl) | Gesubstitueerde androsta-1,4-dieen-3,17-dionen, alsmede farmaceutische preparaten die dergelijke verbindingen bevatten. | |
ES8608535A1 (es) | Procedimiento para preparar una composicion para el tratamiento topico de acne | |
BR9709062A (pt) | Composto, composição farmacêutica, e, uso de um composto. | |
DK0749752T3 (da) | Anvendelse af specifikke RXR-receptor-ligander | |
NZ266314A (en) | Various indane-2-carboxylic acid derivatives substituted by (hetero)aryl-containing moieties and various other indane derivatives as endothelian receptor antagonists and pharmaceutical compositions | |
Dockray et al. | Biological activity of iodinated gastrins | |
ATE138385T1 (de) | Neue steroide mit einer an der 17-stelle spiro- kondensierte methylen-laktongruppe, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und pharmazeutische präparate davon | |
EP0378197A3 (de) | Vitamin-B12-Bestimmung | |
DE59108744D1 (de) | 8-EN-19, 11 beta-ÜBERBRÜCKTE STEROIDE, DEREN HERSTELLUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE | |
Duggan et al. | Enterohepatic recirculation of drugs as a determinant of therapeutic ratio | |
PL309772A1 (en) | Novel compositions based on synegically acting mixture consisting of at least one ligand specific in respect to rxr and at least one ligand specific in respect to rar-a and their application | |
ATE63117T1 (de) | Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung. |